Company ProfilePremium

Alkali Metals Limited

Company Profile Analysis

Tickers: ALKALI.NS, 533029.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Alkali Metals Limited - Company showcase

Year Founded & Workforce

1968

107 Employees

Alkali Metals Limited logo

Alkali Metals Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Alkali Metals Limited Overview

Alkali Metals Limited is one of India's oldest specialist producers of sodium-metal derivatives, a niche class of highly reactive reagents (sodium amide, sodium hydride, sodium alkoxides, sodium azide) used to build drug molecules. Founded in 1968 as a state-backed joint venture in Hyderabad, it has evolved into a promoter-controlled, three-plant manufacturer whose portfolio spans sodium derivatives, picoline/pyridine-based heterocycles (amino-, acetyl- and aminomethyl-pyridines), tetrazoles, cyclic compounds, contract "campaign" fine chemicals and a small slate of APIs from a USFDA-inspected unit in Visakhapatnam. Its customers are predominantly pharmaceutical and agrochemical manufacturers in India and overseas, with exports historically 50–62% of sales. The company is sub-scale (FY2026 revenue INR 93.03 Cr), cyclically profitable, working-capital intensive and governed by a founding family that controls 69.59% of equity. Its investment case rests on technical niche depth and export relationships, offset by thin margins, governance friction and succession uncertainty.


What the company does. Alkali Metals manufactures and sells chemicals. Its exchange letterhead describes it as a manufacturer of "Sodium Amide, Sodium Alkoxides, Sodium Hydride, Sodium Azide, Tetrazoles, Amino Pyridines, Pyridine Derivatives, Cyclic Compounds, Fine Chemicals, Intermediates for pharmaceuticals and Active Pharmaceutical Ingredients" (FY2026 results filing, 26 May 2026). ICRA characterises the company as an ISO 9001/14001-certified maker of sodium metal derivatives, picoline-based compounds and cyclic chemicals, supplied primarily to pharmaceutical companies for bulk-drug production (ICRA rationale, Dec 2024).

Company's own segment framing. In its Ind AS 108 segment note the company states that, because it is "predominantly engaged in the manufacture and sale of chemicals where the risks and returns associated with the products are uniform," its only reportable segments are geographic (Domestic and Export), based on customer location (FY2026 audited results, Note 6).

Business model. The company operates a batch, multi-product, made-to-order chemical manufacturing model:

Catalogue reagents: (sodium derivatives) sold repeatedly to bulk-drug makers who use them as bases, reducing agents or azide sources in API synthesis.

Heterocyclic intermediates: (pyridine derivatives, tetrazoles, cyclic compounds) sold as building blocks to pharma and agrochemical customers.

Campaign fine chemicals: higher-margin, customer-specific molecules produced in discrete campaigns, often for export customers. ICRA explicitly attributed FY2024–FY2025 margin pressure partly to "lower sales of high margin campaign products (fine chemical)" (ICRA, Nov 2024).

APIs: from the Visakhapatnam (JNPC) unit, which received USFDA cGMP status in May 2019 (ICRA, Nov 2019).

Revenue model mix. Essentially 100% product sales. There is no disclosed service, subscription or licensing revenue. Contract manufacturing is embedded within product sales (campaign products) and is not separately disclosed.

Value-chain position. Alkali Metals sits in the upstream-to-midstream portion of the pharmaceutical value chain: it buys basic raw materials (sodium metal or precursors, picolines/pyridine bases, solvents, ammonia, hydrogen-handling infrastructure) and converts them into reagents and intermediates sold to API manufacturers. It also participates one step further downstream through its own API slate. It does not sell finished formulations.

Customer types and end-markets.

ICRA (Sep 2021) noted that the top products together contributed roughly two-thirds of sales in FY2020–FY2021 and that one category accounted for 42% of FY2021 sales, indicating meaningful product concentration.

Independent characterisation. Alkali Metals is best understood as a technically differentiated but commercially sub-scale niche reagent house. Handling metallic sodium and its derivatives (pyrophoric hydrides, explosive azides) requires specialised plant, safety systems and permits, which constitutes a genuine barrier to casual entry. However, the company has not converted this niche into scale: revenue has oscillated between INR 55 Cr and INR 98 Cr for a decade, operating margins have rarely exceeded 13.8%, and returns on equity have averaged ~2% over 10 years (Screener.in compilation). Its earnings are highly sensitive to (a) the timing of export campaign orders, (b) inventory build/release (inventory days 223–494 over FY2015–FY2026), and (c) raw-material and power costs. The business behaves like a job-shop with a quality reputation rather than a platform specialty-chemicals franchise.

Strategy

Stated corporate strategy. The company does not publish an investor presentation, investor-day materials or medium-term strategic plan, and holds no earnings calls. Observable strategic themes from filings and AGM proceedings are:

  1. Succession and continuity of promoter management — the board twice framed Y.V. Prashanth's elevation as part of the succession plan for the MD (EGM Dec 2022; board May 2026).

  2. Working-capital discipline — FY2025 inventory reduction and use of customer advances (ICRA, Jun 2025), carried into FY2026's lower cash conversion cycle (96 days vs. 126).

  3. Cost control — FY2026 reductions in manufacturing expenses (−23%), repairs (−10%) and employee cost (−2%).

  4. Fine-chemicals / campaign product rebuilding — ICRA links profitability to campaign product volumes; management's specific plans are not publicly disclosed.

  5. "Vision 2030" — shareholders asked about the company's 2030 vision and plant visits at the 58th AGM; responses were given by the Company Secretary, but no written targets have been published.

Strategic initiatives in the last 24 months.

Management guidance / medium-term targets: Not publicly disclosed. The company provides no revenue, margin or capex guidance. Third-party projections (e.g., a Tijori Finance scenario table) are not company guidance and are disregarded here.

Products & Services

The company does not disclose product-level revenue, capacity, pricing or launch dates in exchange filings. The catalogue below is assembled from the company's statutory letterhead, ICRA rationales and public company profiles. Pricing is not publicly disclosed for any product (industry practice is negotiated, order-by-order pricing).

Sodium and other metal derivatives (core, legacy franchise)

ProductDescription / functionTypical customer useStatus
Sodium amide (NaNH2)Strong base; aminating agentSynthesis of amino-pyridines, indigo-type chemistry, API intermediatesFlagship legacy product; hydrogen by-product recovered at Unit I
Sodium hydride (NaH)Strong non-nucleophilic base; pyrophoricDeprotonation steps in API synthesisActive (letterhead)
Sodium alkoxides (e.g., sodium methoxide)Bases / catalystsCondensation reactions in pharma and agroActive (letterhead; roic.ai lists sodium methoxide)
Sodium azide (NaN3)Azide source; hazardousTetrazole ring formation for "sartan" antihypertensive APIsActive (letterhead)
Potassium and other metal derivativesAnalogous reagentsSpecialty synthesisListed in catalogue profiles (craft.co)

Tetrazoles

ProductDescriptionCustomer useStatus
Tetrazole derivativesFive-membered nitrogen heterocycles made from azidesSartan-class APIs (e.g., losartan-type chemistry), specialty materialsActive (letterhead); specific grades not disclosed

Pyridine / picoline derivatives

Product familyNamed compoundsCustomer useStatus
Amino pyridinesCategory named on letterhead; specific grades not disclosedPharma intermediatesActive
Aminomethyl pyridines3-(Aminomethyl)pyridine; 4-(Aminomethyl)pyridinePharma/agro building blocksActive (product listing, Wright Research profile)
Acetylpyridine compounds2-Acetylpyridine; 3-Acetylpyridine; 4-Acetylpyridine; 2-Acetyl-4-methylpyridine; N-(6-methyl-2-pyridyl)acetamidePharma/agro intermediates; flavour precursorsActive (product listing)
Other pyridine derivatives2,5-DB3MP (commercialised 2013)Agro/pharma intermediateActive (roic.ai)

Cyclic compounds and fine chemicals

Product familyDescriptionCustomer useStatus
Cyclic compoundsCarbocyclic/heterocyclic intermediatesPharma, agroActive (letterhead)
Fine chemicals ("campaign products")Customer-specific molecules produced in campaigns, mainly for exportInnovator/CDMO customersActive; ICRA notes these are higher-margin and lumpy
Boronic acids, azaindolesCross-coupling and kinase-scaffold building blocksMedicinal chemistry, scale-upListed in catalogue profile (craft.co)
DSSC / OLED materialsElectronic materialsDisplay / solar researchListed in catalogue profile (craft.co)

Active Pharmaceutical Ingredients (Visakhapatnam / JNPC unit)

APITherapeutic classNotes
BenzocaineLocal anaestheticListed API
FluconazoleAntifungalListed API
Loperamide hydrochlorideAntidiarrhoealListed API
Losartan potassiumAntihypertensive (sartan; tetrazole-containing)Strategic fit with in-house azide/tetrazole chemistry
Metformin hydrochlorideAntidiabeticHighly commoditised, large-volume API
Phenylephrine hydrochlorideDecongestantListed API
Rabeprazole sodiumProton-pump inhibitorListed API; pyridine-containing

Source: product listing reproduced in Wright Research company profile (Sep 2026). Regulatory filings (DMFs, CEPs) for these APIs are not disclosed in sources reviewed. The USFDA cGMP status of the Visakhapatnam unit dates to May 2019 (ICRA Nov 2019); the date and outcome of any subsequent USFDA inspection is not publicly disclosed.

Services. No separately disclosed services. Custom synthesis/contract manufacturing is bundled within fine-chemical campaign sales.

Financial Narrative

Sources: FY2022–FY2026 annual figures from Screener.in compilation of audited filings (cross-checked to FY2026 and FY2025 audited results filed 26 May 2026 and 19 May 2025). "EBITDA" = revenue less operating expenses before other income (Screener "operating profit"). Operating income (EBIT) = EBITDA − depreciation. All amounts INR Cr unless stated.

Income statement

Gross profit is not consistently disclosed; the company reports cost of materials and changes in inventory but aggregators reclassify lines inconsistently. From the audited statements, material margin (revenue less materials consumed and inventory change) was INR 38.70 Cr (47.0%) in FY2025 and INR 45.96 Cr (49.4%) in FY2026. StockAnalysis (S&P-sourced) reports gross profit of INR 50.76 Cr (FY2022), 49.11 Cr (FY2023), 48.36 Cr (FY2024), 36.62 Cr (FY2025) and 31.30 Cr (FY2026); its FY2026 figure follows a changed cost classification and is not comparable — discrepancy noted.

Margins and growth

Revenue CAGR: FY2021–FY2026 (5-year) 10.9% (from the COVID-depressed INR 55.38 Cr base); FY2022–FY2026 (4-year) 0.6%; 10-year ~2% (Screener). The 5-year figure flatters; on a normalised base the business has been essentially flat in nominal terms since FY2015 (INR 68.44 Cr).

Balance sheet

Note on discrepancy: the audited FY2026 Statement of Assets and Liabilities shows total assets of INR 95.55 Cr (FY2025: INR 92.94 Cr) and total equity of INR 44.69 Cr (FY2025: INR 44.52 Cr). The Screener total-asset series nets certain deferred-tax items; equity agrees.

Detailed balance sheet, last two years (INR Cr; audited, 26 May 2026):

At 30 September 2026, Screener shows borrowings rising to INR 21.05 Cr, other liabilities INR 31.30 Cr and reserves INR 33.42 Cr (after FY2026 dividend payout), consistent with working capital absorption from higher Q2 FY2027 sales.

Cash flow

Capex for FY2022–FY2024 is derived as operating cash flow less Screener free cash flow; FY2025 audited gross purchase of PP&E was INR 1.31 Cr with INR 0.49 Cr asset-sale proceeds. Dividends paid for FY2022–FY2024 are derived from prior-year DPS × 1.018 Cr shares; FY2025 and FY2026 are as reported in audited cash flow statements. FY2026 working capital absorbed INR 4.91 Cr (receivables +INR 4.68 Cr, inventories +INR 2.15 Cr, offset partly by payables) versus a release of INR 8.19 Cr in FY2025.

Ratios

Current ratio (audited balance sheet): 1.01x at 31 Mar 2025 and 1.13x at 31 Mar 2026; earlier years not computed from sources reviewed. Net debt/EBITDA FY2026 ≈ 2.18x (INR 16.86 Cr / INR 7.72 Cr). ROE, ROA, D/E, coverage and turnover are analyst calculations from Screener data; ROCE and working-capital days are Screener-reported.

Commentary on trends, inflections and drivers

FY2022 — cyclical peak. Revenue surged 64% to INR 91.02 Cr as pharma customers restocked post-COVID and export campaign orders recovered. EBITDA margin reached 12.5% and net profit INR 3.48 Cr, the best result in a decade. Operating cash flow of INR 11.19 Cr allowed debt reduction to INR 17.25 Cr.

FY2023–FY2024 — slow erosion. Revenue slipped 3% and 6% respectively; EBITDA margins compressed from 12.5% to 10.0%. ICRA attributed weakness to low capacity utilisation, lower sales of high-margin campaign fine chemicals and elevated inventory (inventory days peaked at 382 in FY2024). Borrowings rose to INR 23.82 Cr in FY2023 to fund working capital. Interest coverage fell to 1.44x in FY2024, below ICRA's stated downgrade sensitivity of 2x.

FY2025 — the trough. Three consecutive operating losses in Q1–Q3 FY2025 (Q1 operating margin −11.8%) took full-year EBITDA negative (−INR 0.63 Cr). An exceptional charge of INR 2.31 Cr (characterised by one aggregator as a doubtful-debt provision) deepened the pre-tax loss to INR 8.04 Cr. A deferred-tax credit cushioned the net loss to INR 5.80 Cr. Management released working capital aggressively — inventories fell INR 7.39 Cr and healthy customer advances arrived in Q4 (ICRA, Jun 2025) — keeping operating cash flow positive at INR 5.25 Cr despite the loss. Other income included a one-off INR 1.03 Cr lease-liability write-back. The dividend was halved to INR 0.50.

FY2026 — recovery on mix and cost. Revenue grew 13% to a record INR 93.03 Cr. EBITDA recovered to INR 7.72 Cr (8.3% margin), aided by: lower manufacturing expenses (INR 4.55 Cr vs. INR 5.93 Cr), flat power cost, lower employee cost and a sharply lower depreciation charge (INR 2.89 Cr vs. INR 4.15 Cr, as FY2025 included INR 0.77 Cr right-of-use amortisation and assets aged). PBT was INR 3.32 Cr, but net profit was only INR 0.56 Cr because the company reversed INR 1.97 Cr of lapsed, unutilised MAT credit plus INR 0.79 Cr deferred tax. Earnings were extremely back-ended: Q4 FY2026 alone delivered PBT of INR 5.30 Cr against a nine-month loss of INR 1.98 Cr. Cash conversion was poor (CFO/EBITDA 37%) because Q4 export sales were largely uncollected at year end.

FY2027 to date. Q1 FY2027 revenue fell 14.8% YoY to INR 17.57 Cr with an EBITDA loss (−INR 0.34 Cr) as materials cost rose to 79% of revenue and power cost jumped 62% YoY. Q2 FY2027 rebounded strongly: revenue +45.2% YoY to INR 27.27 Cr, EBITDA INR 1.29 Cr (4.7% margin), PAT INR 0.58 Cr (EPS INR 0.56). H1 FY2027 revenue was INR 44.83 Cr (+13.8%) with a near-breakeven net loss of INR 0.07 Cr. TTM (to Sep 2026) revenue is INR 98.48 Cr, EBITDA INR 6.77 Cr and PAT INR 2.57 Cr (Screener). Gross margin pressure is visible: H1 FY2027 materials consumed rose to INR 28.40 Cr from INR 20.85 Cr in H1 FY2026 on 13.8% revenue growth, implying adverse raw material pricing or product mix.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Revenue by Segment (%)

SegmentFY2025FY2026

Domestic revenue (INR Cr)

31.4447.34

Export revenue (INR Cr)

50.8945.69

Total revenue from operations (INR Cr)

82.3393.03

Domestic share of revenue (%)

38.250.9

Export share of revenue (%)

61.849.1

Segment

YoY growth FY2026

Segment operating income

Domestic

+50.6%—

Export

−10.2%—

Total

+13.0%

PBT INR 3.32 Cr (company level)

“—” = not publicly disclosed.

Revenue by Segment

SegmentQ1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Domestic revenue (INR Cr)

9.4211.1216.0910.7211.20

Export revenue (INR Cr)

11.197.668.8218.016.37

Total revenue (INR Cr)

20.6118.7724.9128.7317.57

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (Annual)

SegmentFY2025FY2026

Domestic receivables (INR Cr)

4.724.86

Export receivables (INR Cr)

9.6114.55

Total receivables (INR Cr)

14.3419.41

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

91.0288.2382.8682.3393.03

Operating expenses (INR Cr)

79.6478.5574.5782.9685.31

EBITDA (INR Cr)

11.389.688.29-0.637.72

Depreciation (INR Cr)

3.864.294.604.152.89

Operating income EBIT (INR Cr)

7.525.393.69-4.784.83

Other income incl exceptional (INR Cr)

0.141.050.42-0.750.61

Interest (INR Cr)

2.632.672.562.512.13

Pre-tax income (INR Cr)

5.033.771.55-8.043.31

Net income (INR Cr)

3.482.911.13-5.800.56

EPS basic and diluted (INR)

3.422.861.11-5.700.55

Dividend per share declared for year (INR)

2.002.001.000.501.00

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

EBITDA margin (%)

12.5010.9710.00-0.778.30

Operating EBIT margin (%)

8.266.114.45-5.815.19

Pre-tax margin (%)

5.534.271.87-9.773.56

Net margin (%)

3.823.301.36-7.040.60

Revenue growth YoY (%)

64.36-3.07-6.09-0.6413.00

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets per Screener (INR Cr)

96.75101.92105.5191.0892.87

Shareholders equity (INR Cr)

52.0852.8651.3444.5244.69

Total borrowings (INR Cr)

17.2523.8222.8418.1818.13

Net fixed assets (INR Cr)

46.2749.4747.2941.0338.46

Capital work in progress (INR Cr)

0.631.330.190.000.00

Other liabilities (INR Cr)

27.4225.2431.3328.3830.05

Financial Analysis

Line item31 Mar 202531 Mar 2026

Property, plant & equipment

41.0338.46

Deferred tax asset (MAT credit)

5.233.26

Inventories

26.6928.84

Trade receivables

14.3419.41

Cash & cash equivalents

0.040.05

Other bank balances

0.570.94

Total current assets

46.0053.20

Non-current borrowings

0.230.00

Current borrowings (working capital)

17.6917.85

Total borrowings (filing basis)

17.9217.85

Net debt (borrowings less cash and bank balances)

17.3116.86

Trade payables

19.2526.27

Other current liabilities (incl. customer advances)

7.392.17

Total current liabilities

45.3446.98

Working capital (current assets less current liabilities)

0.666.22

Total equity

44.5244.69

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

11.1911.196.295.252.82

Capital expenditure (INR Cr)

2.863.141.690.820.32

Free cash flow (INR Cr)

8.338.054.604.432.50

Dividends paid (INR Cr)

0.812.042.041.020.51

Share buybacks (INR Cr)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

6.95.52.2-12.11.3

ROA on average assets (%)

3.62.91.1-5.90.6

ROCE as ROIC proxy (%)

11.118.945.99-4.708.67

Debt to equity (x)

0.330.450.440.410.41

Total debt to EBITDA (x)

1.522.462.76-28.862.35

Interest coverage EBIT to interest (x)

2.862.021.44-1.902.27

Asset turnover (x)

0.940.890.800.841.01

Debtor days

53.7456.6379.1663.5776.15

Inventory days

245.90277.93381.69223.28223.59

Payable days

165.04180.30281.00161.04203.67

Cash conversion cycle (days)

134.59154.26179.84125.8296.08

Revenue by Region

RegionFY2025FY2026

Domestic India (INR Cr)

31.4447.34

Export rest of world (INR Cr)

50.8945.69

Revenue by Region (H1FY25–H1FY26)

RegionH1FY25H1FY26

Domestic India (INR Cr)

14.6520.53

Export rest of world (INR Cr)

20.4718.85

Geographic Revenue

RegionFY2026 YoYH1 FY2026 YoYQ1 FY2027 YoY

Domestic

+50.6%+40.1%+18.9%

Export

−10.2%−7.9%−43.1%

Valuation Snapshot

MetricValue

Share price

INR 86.6

Market capitalisation

~INR 88.1 Cr

52-week high / low

INR 106 / INR 46.8

Book value per share

INR 42.8

TTM EPS (to Sep 2026)

INR 2.52

Dividend yield

1.16%

Shares outstanding

1,01,82,506

Free float

30.41%

Share Price & Returns

HorizonReturn

1 year

−2%

3 years (CAGR)

−9%

5 years (CAGR)

0%

10 years (CAGR)

−1%

Valuation Multiples

MultipleAlkali MetalsBasis

P/E (TTM)

34.3x

Screener

P/B

2.0x

INR 86.6 / INR 42.8

EV

~INR 108 Cr

Market cap INR 88.1 Cr + borrowings INR 21.05 Cr (Sep 2026) − cash ~INR 1 Cr

EV/Sales (TTM)

~1.10x

TTM revenue INR 98.48 Cr

EV/EBITDA (TTM)

~16.0x

TTM EBITDA INR 6.77 Cr

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

0.802.002.001.000.501.00

Dividend payout ratio (%)

-67.3158.5169.9790.09-8.78181.79

Credit Ratings

AgencyFacilityRatingOutlookDate

ICRA

Long-term fund-based (INR 18 Cr)

[ICRA]BB+

Stable (revised from Negative)

3–6 Jul 2026

ICRA

Short-term non-fund-based (INR 7 Cr)

[ICRA]A4+

—

3–6 Jul 2026

Moody's / S&P / Fitch

—

Not rated

——

Bucket Details

Bucket31 Mar 2026 (INR Cr)

Current borrowings (≤12 months; working-capital lines)

17.85

Non-current borrowings

0.00

Total

17.85

Analyst Conclusions

Management guidance: None published. Consensus expectations: None (no analyst coverage).

Analyst baseline view (not guidance). H1 FY2027 delivered revenue of INR 44.83 Cr (+13.8%) at near breakeven. If H2 FY2027 follows seasonal patterns (H2 FY2026 revenue INR 53.64 Cr, with a strong Q4), FY2027 revenue in the region of INR 95–105 Cr is plausible, but the margin outcome hinges on raw-material and power costs and on Q4 export campaigns. With the MAT-credit reversal largely behind (deferred tax asset reduced to INR 3.26 Cr), reported tax drag should be smaller than in FY2026.

Bull case

  1. Operating leverage on spare capacity: Q4 FY2026 showed a 21% EBITDA margin at INR 28.7 Cr quarterly revenue; Q2 FY2027 delivered INR 27.3 Cr. Sustaining ~INR 27–29 Cr quarterly revenue without capex could lift annual EBITDA well above the FY2022 peak of INR 11.4 Cr.

  2. Domestic substitution momentum: Domestic revenue grew 50.6% in FY2026 and 18.9% in Q1 FY2027, diversifying away from volatile export campaigns.

  3. Credit and governance repair: ICRA's Stable outlook, an unmodified audit under a new auditor, and a potential EGM approval for the ED could narrow the governance discount.

Bear case

  1. Earnings quality and fragility: FY2026 profit came entirely from Q4; Q1 FY2027 relapsed to a loss; 10-year ROE ~2%. At 34x TTM earnings and ~16x EV/EBITDA, the stock prices in a durable recovery the record does not support.

  2. Working-capital and credit risk: Export receivables spiked to INR 14.55 Cr at Mar 2026 and borrowings rose to INR 21.05 Cr by Sep 2026; a repeat of FY2025's INR 2.31 Cr exceptional charge would erase a year's profit.

  3. Governance overhang: Public shareholders blocked the MD's reappointment and the ED's appointment; the MD (74) faces term expiry on 30 Apr 2027; 30% of promoter shares are pledged; no institutional holders.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Q4 CY2026EGM to approve Y.V. Prashanth as ED — outcome and voting pattern
By Apr 2027Resolution of MD succession before 30 Apr 2027 term expiry
Mid-Jan / Feb 2027Q3 FY2027 results — margin sustainability, export recovery
May 2027FY2027 audited results — receivable provisions, cash conversion, dividend
OngoingExport receivable collection vs. Mar 2026 peak (INR 14.55 Cr)
OngoingPower & fuel and raw-material cost trajectory amid 11.4% WPI inflation
Mid-2027ICRA annual surveillance — interest coverage vs. 2x trigger
OngoingAny USFDA inspection outcome at Visakhapatnam
OngoingPromoter pledge changes

Concluding analyst verdict

Alkali Metals is a genuine specialist trapped in a sub-scale, cyclical business model. Its five-decade franchise in sodium-metal derivatives, heterocyclic intermediates and a USFDA-inspected API plant constitutes real, hard-to-replicate technical capability, and the FY2026 recovery — record revenue of INR 93.03 Cr, EBITDA back to INR 7.72 Cr, and a Q4 that printed a 21% margin — demonstrates what the asset base can earn when campaign orders and plant loading align. Q2 FY2027's 45% revenue growth and return to profit reinforce that the FY2025 trough was cyclical rather than terminal.

Yet the long-run evidence is unflattering. Revenue has barely moved in nominal terms since FY2015, ten-year ROE averages about 2%, cash conversion is erratic, and inventory days of 220–380 tie up most of the balance sheet. Profitability remains hostage to a handful of export campaigns and to input costs that are now rising sharply. Reported earnings are further muddied by MAT-credit reversals and exceptional items, making TTM EPS of INR 2.52 a fragile anchor for a 34x multiple.

Governance is the swing factor. The August 2026 rejection of both the managing director's reappointment and his son's executive appointment — however small the voting public — creates a hard deadline: the MD's term ends 30 April 2027. A clean EGM outcome and an articulated succession and growth plan would materially de-risk the story; a prolonged impasse would compound an already illiquid, uncovered, pledge-encumbered stock.

On balance, the dossier supports a cautious/neutral stance: the operating trough appears to have passed and credit risk has eased (ICRA Stable), but valuation now discounts sustained mid-cycle margins that the company has rarely held for more than a few quarters. Evidence of two to three consecutive quarters of 8%+ EBITDA margins with positive operating cash flow, together with resolved leadership, would be required to move to a constructive view.


Prepared from public filings and data sources available as of 19 October 2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundAge

Y.S.R. Venkata Rao (Yerramilli Sri Rama Venkata Rao), DIN 00345524

Managing Director; promoter (67.81% holding)

MD since 1 May 2004 (22+ years); briefly Compliance Officer Jan–May 2017

Long-serving promoter-manager

74 (Simply Wall St)

Y.V. Prashanth, DIN 00345418

Executive Director (re-appointed by board 12 Oct 2026, subject to EGM); previously ED Nov 2022–Nov 2025; Non-Executive Director Nov 2025–Oct 2026

Board member since Nov 2022 (earlier stint as ED before that)

B.Pharm (Andhra University); MS Pharmacy (USA); experience in liquidity management, client development, marketing, receivables/payables management; son of the MD

—

Gayathri Kesavarapu

Chief Financial Officer

In role by May 2026 (start date not disclosed); predecessor K. Uma Kumari per database records

——

Siddharth Dubey

Company Secretary & Compliance Officer

In role since at least May 2025

——

V.V. Viswanadha Sarma

General Manager – Production

—

Per craft.co

—

“—” = not publicly disclosed.

Board of Directors

NameRoleCategoryNotes

Dr. J.S. Yadav

Chairman

Independent

—

Y.S.R. Venkata Rao

Managing Director

Executive, promoter

Current term ends 30 Apr 2027; reappointment rejected by shareholders 21 Aug 2026

Y.V. Prashanth

Executive Director (from 12 Oct 2026, subject to EGM)

Executive, promoter group

AGM special resolution failed 21 Aug 2026

Mrs. Y. Lalithya Poorna

Director

Non-executive, promoter group (1.08% holder, foreign promoter category)

Re-appointed on rotation Aug 2026; on board since at least 2012

Dr. A.R. Prasad

Director

Non-executive, non-independent

Appointed additional director Feb 2021

K.V. Suryaprakash Rao (Kotamarthy Venkata Suryaprakash Rao)

Director

Independent

—

G. Jayaraman

Director

Independent

On board since at least 2012 (long tenure)

Murali Krishna Chevuturi

Director

Independent

—

T.V. Rao (Thallapaka V. Rao)

Director

Independent

—

Sivarama Prasad Bhamidi, DIN 07620679

Director

Independent

Appointed 20 Jul 2026 for five years (to 19 Jul 2031); background in defence and insolvency per news coverage

Board & Management Changes

DateChangeContext

18 Jul 2025

Statutory auditor resigned; J V S L & Associates appointed

Company stated outgoing auditor raised no concerns

10 Nov 2025

Y.V. Prashanth's ED tenure completed; continued as non-executive

Three-year term from Nov 2022 lapsed

26 May 2026

Board proposes Prashanth as ED (from 1 Jun 2026) and MD reappointment (from 1 May 2027)

Described as succession planning

9–10 Jun 2026

Independent director resigns (health)

Committees reconstituted

20 Jul 2026

S.P. Bhamidi appointed independent director

Approved at AGM

21 Aug 2026

Shareholders reject MD reappointment (63.26% for vs. 36.74% against among public votes) and Prashanth's ED appointment (70.93% for vs. 29.07% against); promoters abstained

Special resolutions need 75%; MD aged over 70 requires special resolution

12 Oct 2026

Board re-appoints Prashanth as ED for 3 years from 12 Oct 2026, subject to EGM

EGM date not yet announced in sources reviewed

Major Shareholders

HolderShares% of equityNotes

Yerramilli Sri Rama Venkata Rao

69,04,715

67.81

MD / promoter

Yerramilli Lalithya Poorna

1,10,000

1.08

Promoter group (foreign)

Nagalakshmi Kumari Yerramilli

41,5000.41

Promoter group

Krishnaveni Yerramilli

28,9940.28

Promoter group

CDC Industrial Infras Limited

6330.01

Promoter group

Total promoter & promoter group

70,85,842

69.59

21,30,000 shares pledged = 30.06% of promoter holding / 20.92% of total equity (Dec 2025)

Public (≈12,780 shareholders, Jun 2026)

30,96,664

30.41

Predominantly resident individuals

FIIs / FPIs

00.00

Exited by Dec 2024 (was 0.55% Mar 2022)

Mutual funds

00.00—

Other DIIs / insurers

00.00—

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypeRelative positioning vs. Alkali Metals

Pyridine & picoline derivatives

Jubilant Ingrevia Ltd (India)

Listed, integrated

Global-scale pyridine producer; described by broker research as the only scaled non-Chinese pyridine producer; FY2026 revenue ~INR 4,388 Cr — roughly 47x Alkali Metals

Pyridine & picoline derivatives

Vertellus (USA, private)

Integrated pyridine producer

Major Western supplier; financials not public

Pyridine & picoline derivatives

Nanjing Red Sun (China)

Integrated pyridine producer

Large Chinese supplier; low-cost

Sodium alkoxides

Evonik Industries (Germany)

Global chemical major

Leading alkoxide producer; scale and integration far larger

Sodium alkoxides

BASF (Germany)

Global chemical major

Sodium methylate producer; scale

Sodium hydride / reactive metal reagents

Chinese and Indian reagent makers (fragmented, many unlisted)

Mixed

Price competition in commodity grades

Sodium azide / tetrazoles

Chinese and Indian azide producers (unlisted)

Mixed

Sartan supply chain; regulatory sensitivity

APIs — metformin

Granules India, Aarti Drugs (India)

Listed API majors

Massive scale in metformin; Alkali Metals is marginal

APIs — losartan / sartans

IPCA Laboratories, Zydus (India) and Chinese makers

Listed / integrated

Integrated sartan chains; Alkali Metals small

Custom synthesis / fine chemicals

Indian CDMOs (e.g., Jubilant Ingrevia CDMO, numerous unlisted Hyderabad custom-synthesis houses)

Mixed

Competes on niche chemistry and flexibility

Peer Comparison FY2026

MetricAlkali MetalsJubilant Ingrevia

Revenue

INR 93.03 Cr

~INR 4,388 Cr (consolidated)

Revenue growth

+13.0%+5%

EBITDA margin

8.3%

~13–14% (EBITDA INR 567–607 Cr; sources differ)

R&D intensity

1.34%—

Net debt / EBITDA

~2.2x

~0.99x

Company Snapshot

$10.7M

Revenue

107

Employees

1968

Founded

Hyderabad, India

Headquarters

SWOT Analysis

Strengths

  • Longevity and niche expertise: Operating since 1968 in hazardous sodium chemistry; ICRA repeatedly cites "long track record of more than three decades" as a rating strength (ICRA, Dec 2023, Jul 2026).
  • Regulatory-grade asset: Visakhapatnam unit obtained USFDA cGMP status in May 2019 (ICRA, Nov 2019), enabling regulated-market API sales.
  • Moderate leverage: Debt/equity 0.41x and total borrowings INR 17.85 Cr at FY2026 (audited), primarily working-capital in nature (ICRA).
  • Demonstrated operating leverage: Q4 FY2026 EBITDA margin 21.2% on INR 28.73 Cr revenue (Screener), showing profitability potential at higher volumes.
  • Diversified geography: FY2026 revenue split 50.9% domestic / 49.1% export (Note 6, FY2026 results), reducing single-market dependence.
  • Consistent dividend culture: Dividend paid in every year shown, including loss-making FY2025 (INR 0.50) and FY2021 (~INR 0.80); FY2026 INR 1.00.
  • Committed promoter ownership: 69.59% promoter stake unchanged since 2022 (shareholding filings).

Weaknesses

  • Chronic low returns: 10-year average ROE ~2% and 3-year ROE −1% (Screener); FY2026 ROE 1.3%.
  • Earnings volatility: Quarterly EBITDA margins ranged from −11.8% (Q1 FY2025) to +21.2% (Q4 FY2026) within two years.
  • Working-capital intensity: Inventory days 224–382 over FY2022–FY2026; ICRA cites buffer inventory for sudden export orders and long processing times.
  • Weak cash conversion in FY2026: CFO INR 2.82 Cr vs. EBITDA INR 7.72 Cr (37%); receivables up INR 4.68 Cr.
  • Low R&D intensity: 1.34% of revenue in FY2026 (INR 1.25 Cr).
  • Thin liquidity: Cash and bank balances under INR 1 Cr at 31 Mar 2026; reliance on INR 18 Cr working-capital lines.
  • Tax-asset erosion: INR 1.97 Cr of MAT credit lapsed and was reversed in FY2026, wiping out most of the year's PBT.

Opportunities

  • Domestic import substitution: Domestic revenue grew 50.6% in FY2026, indicating traction with Indian API makers.
  • Spare capacity: ICRA notes low capacity utilisation; incremental volumes can lift margins without capex (CWIP nil, capex INR 0.32 Cr in FY2026).
  • Campaign fine-chemical recovery: ICRA links margin pressure to lower campaign sales; Q4 FY2026 export spike (INR 18.01 Cr) shows demand can return.
  • API leverage of in-house chemistry: Losartan and rabeprazole APIs use the company's azide/tetrazole and pyridine know-how.
  • Credit-profile improvement: ICRA outlook revised to Stable (Jul 2026); sustained coverage above 2x could support better financing terms.
  • Succession clarity: Resolving the ED/MD question at an EGM could reduce governance discount.

Threats

  • Leadership vacuum: MD's reappointment from 1 May 2027 was rejected at the 21 Aug 2026 AGM; current term ends 30 Apr 2027.
  • Receivable credit risk: Export receivables of INR 14.55 Cr at Mar 2026 (Note 6) vs. INR 2.31 Cr exceptional charge in FY2025.
  • Input cost inflation: Q1 FY2027 power & fuel +62% YoY and materials at 79% of revenue; national WPI inflation 11.4% (Sep 2026, ICRA research).
  • Rising interest rates: CPI-driven rate hikes signalled (ICRA research, Oct 2026) increase cost of INR 21 Cr working-capital debt (Sep 2026).
  • Chinese competition: Global pyridine and reagent supply dominated by large Chinese and integrated producers.
  • Promoter pledge: 20.92% of total equity pledged (Dec 2025); forced selling risk in a downturn.
  • Liquidity of the stock: Trades in tiny volumes (e.g., 22 shares traded on BSE on 12 Oct 2026, EquityBulls), limiting investability.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
19 May 2025FY2025 audited results: revenue INR 82.33 Cr, net loss INR 5.80 Cr; dividend cut to INR 0.50; secretarial auditor proposedConfirms trough year
5–6 Jun 2025ICRA reaffirms [ICRA]BB+ (Negative)/A4+; notes Q4 FY2025 return to operating profit and customer advancesCredit pressure acknowledged
10 Jul 2025Reg 30 disclosure initiating auditor changeGovernance event
18 Jul 2025Q1 FY2026 results: revenue INR 20.61 Cr; net loss INR 1.15 Cr (incl. MAT reversal); J V S L & Associates appointed auditorLosses continue; auditor replaced
19 Jul 2025Outgoing auditor's resignation letter filed; company states no concerns raisedMitigates red-flag reading
14 Aug 2025Record date for FY2025 dividend—
21 Aug 202557th AGM: all seven resolutions passed, incl. auditor appointmentRoutine
30 Sep 2025Shareholding: promoter pledge steady at 30.05% of holdingOngoing risk factor
7 Nov 2025Q2 FY2026 results: revenue INR 18.77 Cr (−8% YoY); net loss INR 0.91 Cr; exports INR 7.66 Cr vs. domestic INR 11.12 CrRevenue weak, loss narrows
7 Nov 2025Board notes end of Prashanth's ED tenure (10 Nov 2025); continues as non-executiveSuccession pause
21 Nov 2025New Indian labour codes take effect; company later states no material impactRegulatory
31 Dec 2025Trading window closed pending Q3 resultsRoutine
14 Feb 2026Q3 FY2026 results: revenue INR 24.91 Cr (+11.5% YoY); net loss INR 1.39 Cr vs. INR 4.93 Cr loss a year earlier; domestic +155%, exports −45%Mix shift to domestic
Apr 2026Promoters declare no new encumbrance during FY2026Pledge not increased
10 Apr 2026Company clarifies share-price movement in response to exchange queryVolatility in thinly traded stock
15–16 Apr 2026Reg 74(5) compliance certificate for Q4 FY2026Routine
26 May 2026FY2026 results: record revenue INR 93.03 Cr; PBT INR 3.32 Cr; PAT INR 0.56 Cr after INR 1.97 Cr MAT credit reversal; Q4 PAT INR 4.02 Cr; dividend INR 1; ED and MD resolutions proposedTurnaround year
29–30 May 2026Record date fixed for dividend at 58th AGM—
9–10 Jun 2026Independent director resigns (health); committees reconstituted 9 JunBoard change
3–6 Jul 2026ICRA reaffirms BB+/A4+; outlook revised to Stable from NegativeCredit improvement
20 Jul 2026Q1 FY2027 results: revenue INR 17.57 Cr (−14.8% YoY); net loss INR 0.64 Cr; power cost +62% YoY; S.P. Bhamidi appointed IDWeak start to FY2027
29 Jul 202658th AGM notice circulated with FY2026 annual report—
5 Aug 2026Book closure 15–21 Aug; record date 14 Aug—
21 Aug 202658th AGM: dividend, accounts, ID appointment approved; MD reappointment and ED appointment rejected (promoters abstained)Major governance event
5 Oct 2026Board meeting intimation for Q2 results—
12 Oct 2026Q2 FY2027 results: revenue INR 27.27 Cr (+45.2% YoY); PAT INR 0.58 Cr; EPS INR 0.56; H1 net loss INR 0.07 Cr; board re-appoints Prashanth as ED subject to EGMProfit recovery; governance replay
12 Oct 2026Correction of Prashanth's DIN in board outcomeAdministrative
17 Oct 2026Reg 74(5) certificate for quarter ended 30 Sep 2026Routine

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 910.2 Mn in FY2022 to INR 930.3 Mn in FY2026.
Alkali Metals Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations910.2882.3828.6823.3930.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.